Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

1997 - Is surgical resection beneficial in recurrent or metastatic gastric cancer?

Date

09 Sep 2017

Session

Poster display session

Topics

Surgical Oncology;  Radiation Oncology;  Gastric Cancer

Presenters

YongWon Choi

Citation

Annals of Oncology (2017) 28 (suppl_5): v209-v268. 10.1093/annonc/mdx369

Authors

Y. Choi, M.S. Ahn, H.W. Lee, S.Y. Kang, J. Choi

Author affiliations

  • Department Of Hematology-oncology, Ajou University School of Medicine, 443-721 - Suwon/KR
More

Resources

Abstract 1997

Background

Although chemotherapy is currently established as a standard treatment in recurrent or metastatic gastric cancer, the role of palliative surgical resection is still controversial. We investigated the survival benefit of surgical resection in patients (pts) with recurrent or metastatic gastric cancer who received systemic chemotherapy.

Methods

A retrospective review was conducted on 696 pts who received palliative chemotherapy for recurrent (n = 307) or primary metastatic (n = 389) gastric cancer. Overall survival (OS) of pts who underwent surgical resection followed by chemotherapy was compared to that of pts who received chemotherapy alone.

Results

Among 138 pts (primary metastatic: 96, recurrent: 42) with surgical resection, gastrectomy, metastasectomy, and gastrectomy with metastasectomy were performed in 83 (primary metastatic: 81), 42, and 13 pts, respectively. Higher surgical resection rate was observed in pts with young age (

Conclusions

The present study suggests that judicious use of surgical resection before chemotherapy in recurrent or metastatic gastric cancer pts may result in favorable outcome, although large scale phase III trials are essential to establish this treatment approach as a standard practice.

Clinical trial identification

Legal entity responsible for the study

Ajou University School of Medicine

Funding

Samyang Biopharmaceuticals Corporation, Korea

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.